Security
Viking Therapeutics Inc. Warrants · VKTXW
VKTXWNASDAQWarrantHistorical · closed Apr 8, 2021CIK 1607678Updated Nov 6, 2026
Current security for this SEC filerVKTX · NASDAQ
VKTXW price & chart
Historical security
This listing closed Apr 8, 2021. Live provider charts are shown only for current listings.
Current security: VKTX
About the company
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company advancing a next-generation portfolio of therapies for obesity and metabolic disease. Guided by deep expertise in metabolic biology and rigorous science, Viking is developing innovative treatments to help people achieve meaningful, lasting health improvements by treating obesity first. The company's lead program, VK2735, is a dual glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist in development in both subcutaneous and oral formulations for obesity. VK2735 is currently being evaluated in Phase 3 clinical studies for obesity, along with maintenance dosing strategies designed to support long-term weight management. Viking is also advancing additional obesity programs, including VK3019, an amylin receptor agonist, VK2809, an orally available thyroid hormone receptor beta agonist for metabolic and liver disease, and VK0214 for the rare genetic disorder X-linked adrenoleukodystrophy (X-ALD).
In the news
No coverage from other publishers is available.
Recent filings
SCHEDULE 13G/A - filed by FMR LLC regarding Viking Therapeutics, Inc.
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Items 1.01, 2.03, 9.01
424B5 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 739,415,000Source | 937,888,000Source | 521,898,000Source | 827,851,000Source | 946,839,000Source | 608,242,000Source | 866,993,000Source | 967,518,000Source | 715,729,000Source | 908,321,000Source | 368,490,000Source | 168,529,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 100,376,000Source | 50,347,000Source | 125,750,000Source | 33,880,000Source | 43,915,000Source | 118,116,000Source | 37,940,000Source | 195,579,000Source | 165,810,000Source | 26,676,000Source | 55,516,000Source | 36,632,000Source |
| Assets, CurrentUSD | 738,703,000Source | 936,649,000Source | 517,564,000Source | 827,017,000Source | 945,724,000Source | 608,209,000Source | 866,023,000Source | 966,335,000Source | 715,598,000Source | 907,216,000Source | 367,225,000Source | 167,040,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 2,242,000Source | 1,733,000Source | 941,000Source | 2,815,000Source | 138,000Source | 1,224,000Source | 865,000Source | 643,000Source | 1,806,000Source | 1,128,000Source | 2,522,000Source | 3,411,000Source |
| Operating Lease, Right-of-Use AssetUSD | 666,000Source | 1,113,000Source | 4,010,000Source | 780,000Source | 977,000Source | 0Source | 892,000Source | 1,052,000Source | 85,000Source | 1,003,000Source | 1,126,000Source | 1,418,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 26,385,000Source | 26,440,000Source | 113,581,000Source | 32,390,000Source | 25,859,000Source | 106,325,000Source | 20,075,000Source | 33,626,000Source | 76,667,000Source | 28,043,000Source | 20,071,000Source | 23,207,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 1,000Source | 1,000Source | 1,000Source | 1,000Source | 1,000Source | 1,000Source | 1,000Source | 1,000Source | 1,000Source | 1,000Source | 1,000Source | 1,000Source |
| Retained Earnings (Accumulated Deficit)USD | -689,884,000Source | -452,490,000Source | -1,133,893,000Source | -599,097,000Source | -427,550,000Source | -1,005,871,000Source | -533,536,000Source | -405,299,000Source | -847,546,000Source | -487,907,000Source | -377,944,000Source | -292,049,000Source |
| Stockholders' Equity Attributable to ParentUSD | 713,030,000Source | 911,448,000Source | 408,317,000Source | 795,461,000Source | 920,980,000Source | 501,917,000Source | 846,918,000Source | 933,892,000Source | 639,062,000Source | 880,278,000Source | 348,419,000Source | 145,322,000Source |
| Additional Paid in Capital, Common StockUSD | 1,402,539,000Source | 1,362,305,000Source | 1,543,362,000Source | 1,394,723,000Source | 1,350,801,000Source | 1,508,643,000Source | 1,380,669,000Source | 1,340,789,000Source | 1,486,229,000Source | 1,368,972,000Source | 733,546,000Source | 445,267,000Source |
| Liabilities and EquityUSD | 739,415,000Source | 937,888,000Source | 521,898,000Source | 827,851,000Source | 946,839,000Source | 608,242,000Source | 866,993,000Source | 967,518,000Source | 715,729,000Source | 908,321,000Source | 368,490,000Source | 168,529,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 26,067,000Source | 25,685,000Source | 109,656,000Source | 31,980,000Source | 25,093,000Source | 106,325,000Source | 19,573,000Source | 32,774,000Source | 76,667,000Source | 27,413,000Source | 19,135,000Source | 21,947,000Source |
| Operating Lease, Liability, CurrentUSD | 437,000Source | 480,000Source | 161,000Source | 468,000Source | 334,000Source | 0Source | 498,000Source | 329,000Source | 137,000Source | 489,000Source | 324,000Source | 304,000Source |
| Accounts Payable, CurrentUSD | 4,413,000Source | 254,000Source | 69,012,000Source | 5,494,000Source | 11,090,000Source | 67,183,000Source | 7,702,000Source | 5,225,000Source | 53,251,000Source | 9,813,000Source | 7,512,000Source | 8,529,000Source |
| Operating Lease, Liability, NoncurrentUSD | 318,000Source | 755,000Source | 3,925,000Source | 410,000Source | 766,000Source | 0Source | 502,000Source | 852,000Source | 0Source | 630,000Source | 936,000Source | 1,260,000Source |
| Additional Financial Items | ||||||||||||
| AOCI, Debt Securities, Available-for-sale, Adjustment, after TaxUSD | 374,000Source | 1,632,000Source | -1,153,000Source | -166,000Source | -2,272,000Source | -856,000Source | -216,000Source | -1,599,000Source | 378,000Source | -788,000Source | -389,000Source | -1,102,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 247,000Source | 281,000Source | 315,000Source | 397,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -158,325,000Source | -45,629,000Source | -359,639,000Source | -109,963,000Source | -85,895,000Source | -68,867,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | 7,336,000Source | 8,982,000Source | 11,133,000Source | 13,547,000Source | 10,337,000Source | 11,348,000Source | 40,818,000Source | 29,712,000Source | 16,750,000Source | 8,673,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 13,931,000Source | -2,110,000Source | 43,438,000Source | 2,303,000Source | -1,018,000Source | 7,085,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -113,976,000Source | -52,331,000Source | -278,685,000Source | -87,790,000Source | -73,376,000Source | -48,397,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 54,189,000Source | 63,245,000Source | 341,388,000Source | -553,366,000Source | -179,086,000Source | 54,753,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | — | — | 0Source | 42,101,000Source | 7,121,000Source | 1,533,000Source |
| Payments for Repurchase of Common StockUSD | — | — | — | — | — | — | — | — | — | — | — | 6,795,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 12,077,000Source | 349,000Source | 76,439,000Source | 612,464,000Source | 271,376,000Source | 4,163,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | — | — | — | — | — | 10,519,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | — | — | — | — | — | 36,632,000Source |
| Additional Financial Items | ||||||||||||
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | — | — | — | — | — | — | — | — | 10,000Source | — | 0Source | -42,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | 0Source | 2,000Source | 2,000Source | 24,000Source | 16,000Source | 9,000Source | — | — | — | 0Source |
| General and Administrative ExpenseUSD | — | — | 8,608,000Source | 13,771,000Source | 16,843,000Source | 14,421,000Source | 13,975,000Source | 14,078,000Source | 48,387,000Source | 49,277,000Source | 37,021,000Source | 16,121,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 1,000Source | 1,000Source | 1,000Source | 1,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -90,787,000Source | -24,940,000Source | -128,022,000Source | -65,561,000Source | -158,325,000Source | -45,629,000Source | -359,639,000Source | -109,963,000Source | -85,895,000Source | -68,867,000Source |
| Operating ExpensesUSD | — | — | 98,561,000Source | 36,556,000Source | 132,597,000Source | 74,574,000Source | 164,125,000Source | 55,469,000Source | 393,342,000Source | 150,921,000Source | 100,827,000Source | 70,355,000Source |
| Operating Lease, ExpenseUSD | — | — | 123,000Source | 97,000Source | 252,000Source | 119,000Source | 119,000Source | 124,000Source | 500,000Source | 404,000Source | 339,000Source | 340,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 7,774,000Source | 11,616,000Source | 4,575,000Source | 9,013,000Source | 5,800,000Source | 9,840,000Source | 33,703,000Source | 40,958,000Source | 14,932,000Source | 1,488,000Source |
| Payments to Acquire InvestmentsUSD | — | — | — | — | — | — | 72,437,000Source | 232,614,000Source | 418,037,000Source | 1,113,368,000Source | 478,303,000Source | 121,431,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | 300,000Source | — | 10,400,000Source | 6,400,000Source | 0Source |
| Realized Investment Gains (Losses)USD | — | — | — | — | 30,000Source | 4,000Source | — | — | 55,000Source | 112,000Source | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Operating Income (Loss)USD | — | — | -98,561,000Source | -36,556,000Source | -132,597,000Source | -74,574,000Source | -164,125,000Source | -55,469,000Source | -393,342,000Source | -150,921,000Source | -100,827,000Source | -70,355,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 7,774,000Source | 11,616,000Source | 4,575,000Source | 9,013,000Source | 5,800,000Source | 9,840,000Source | 33,703,000Source | 40,958,000Source | 14,932,000Source | 1,488,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -359,639,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 1,000Source | 1,000Source | 1,000Source | 1,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -90,787,000Source | -24,940,000Source | -128,022,000Source | -65,561,000Source | -158,325,000Source | -45,629,000Source | -359,639,000Source | -109,963,000Source | -85,895,000Source | -68,867,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.81Source | -0.22Source | -1.1Source | -0.58Source | -1.37Source | -0.41Source | -3.19Source | -1.01Source | -0.91Source | -0.9Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.81Source | -0.22Source | -1.1Source | -0.58Source | -1.37Source | -0.41Source | -3.19Source | -1.01Source | -0.91Source | -0.9Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 112,319,770Source | 110,910,704Source | 116,262,723Source | 112,134,425Source | 115,568,078Source | 112,069,078Source | 112,667,303Source | 109,037,122Source | 94,346,991Source | 76,833,630Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 112,319,770Source | 110,910,704Source | 116,262,723Source | 112,134,425Source | 115,568,078Source | 112,069,078Source | 112,667,303Source | 109,037,122Source | 94,346,991Source | 76,833,630Source |
| Additional Financial Items | ||||||||||||
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | 0Source | 2,000Source | 2,000Source | 24,000Source | 16,000Source | 9,000Source | — | — | — | 0Source |
| General and Administrative ExpenseUSD | — | — | 8,608,000Source | 13,771,000Source | 16,843,000Source | 14,421,000Source | 13,975,000Source | 14,078,000Source | 48,387,000Source | 49,277,000Source | 37,021,000Source | 16,121,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -203,522,000Source | — | — | — |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | 7,772,000Source | 11,531,000Source | 4,545,000Source | 9,033,000Source | 5,800,000Source | 9,864,000Source | 33,704,000Source | 40,940,000Source | 15,020,000Source | 1,589,000Source |
| Operating ExpensesUSD | — | — | 98,561,000Source | 36,556,000Source | 132,597,000Source | 74,574,000Source | 164,125,000Source | 55,469,000Source | 393,342,000Source | 150,921,000Source | 100,827,000Source | 70,355,000Source |
| Operating Lease, ExpenseUSD | — | — | 123,000Source | 97,000Source | 252,000Source | 119,000Source | 119,000Source | 124,000Source | 500,000Source | 404,000Source | 339,000Source | 340,000Source |
| Realized Investment Gains (Losses)USD | — | — | — | — | 30,000Source | 4,000Source | — | — | 55,000Source | 112,000Source | — | — |
| Research and Development ExpenseUSD | — | — | 89,953,000Source | 22,785,000Source | 115,754,000Source | 60,153,000Source | 150,150,000Source | 41,391,000Source | 344,955,000Source | 101,644,000Source | 63,806,000Source | 54,234,000Source |
Offerings
Registration 333-297820
Filing attachments
vktx-ex99_1.htm · 8-K · 2026-10-28
Exhibit 99.1 Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update -- VANQUISH Phase 3 Trials for Subcutaneous VK2735 in Obesity Continue to Advance -- -- SUNRISE Phase 3 Trials for Oral VK2735 Initiated -- -- Positive Top-Line Results Announced for VK2735 Maintenance Dosing Study; Part 2 Study Initiated -- -- Phase 1 SAD Study of Amylin Agonist VK3019 Nearing Completion -- -- Strong Quarter-End Cash Position of $960 Million -- Conference call sche…
Read attachment ↗vktx-ex4_1.htm · 8-K · 2026-09-28
Exhibit 4.1 Viking Therapeutics, Inc. INDENTURE Dated as of September 25, 2026 U.S. Bank Trust Company, National Association Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other D…
Read attachment ↗vktx-ex4_2.htm · 8-K · 2026-09-28
Exhibit 4.2 Execution Version ═══════════════════════════════════════════════════════ ═══════════════════════════════════════════════════════ Viking Therapeutics, Inc. and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION as Trustee ───────────────────── first SUPPLEMENTAL INDENTURE Dated as of September 25, 2026 ───────────────────── 2.00% Convertible Senior Notes due 2032 ═══════════════════════════════════════════════════════ ═══════════════════════════════════════════════════════ …
Read attachment ↗vktx-ex99_1.htm · 8-K · 2026-09-22
Exhibit 99.1 Viking Therapeutics Announces Positive Topline Results from Maintenance Study of GLP-1/GIP Agonist VK2735 Demonstrating the Promise of Multiple Maintenance Dosing Regimens 22% Placebo-Adjusted Weight Loss Reported at Week 33 Following Weekly Dosing of VK2735 at 17.5 mg; No Plateau Observed Results Demonstrate Viability of Monthly and Every Other Week Dosing Regimens for Maintaining Weight Loss; Increasing Options for Adherence to Treatment Up to 97% of Weight Loss Maintained Fol…
Read attachment ↗vktx-ex4_2.htm · S-3ASR · 2026-07-30
Exhibit 4.2 Viking Therapeutics, Inc. INDENTURE Dated as of [ ] [ ] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions …
Read attachment ↗vktx-ex99_1.htm · 8-K · 2026-07-29
EX-99.1 2 vktx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today -- Phase 3 VANQUISH 1 & 2 Trials for Subcutaneous VK2735 in Obesity Fully Enrolled and Advancing -- -- Oral Phase 3 VK2735 Trial Initiation Expected 4Q26 -- -- VK2735 Maintenance Dosing Data Expected 3Q26 -- -- Phase 1 Study of Amylin Agonist VK3019 Underway -- -- Strong Quarter-End Cash…
Read attachment ↗